^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PMAIP1 overexpression

i
Other names: PMAIP1, Phorbol-12-Myristate-13-Acetate-Induced Protein 1, Immediate-Early-Response Protein APR, PMA-Induced Protein 1, Protein Noxa, NOXA, Adult T Cell Leukemia-Derived PMA-Responsive, APR
Entrez ID:
Related biomarkers:
Associations
Trials
8ms
PMAIP1 promotes J subgroup avian leukosis virus replication by regulating mitochondrial function. (PubMed, Poult Sci)
Furthermore, we observed that PMAIP1 promotes virus replication by modulating mitochondrial function. In conclusion, the PMAIP1 gene facilitates virus replication by regulating mitochondrial function, thereby enriching our understanding of mitochondria-related genes and their involvement in ALV-J infection, offering valuable insights for avian leukosis disease resistance strategies.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1)
|
PMAIP1 overexpression
8ms
Noxa inhibits oncogenesis through ZNF519 in gastric cancer and is suppressed by hsa-miR-200b-3p. (PubMed, Sci Rep)
Upregulation of Noxa expression suppressed the tumorigenesis of GC in vivo. The current investigation sheds light on the pivotal role of the hsa-miR-200b-3p/Noxa/ZNF519 axis in elucidating the pathogenesis of gastric cancer, offering a promising avenue for targeted therapeutic interventions in the management of this challenging malignancy.
Journal
|
BCL6 (B-cell CLL/lymphoma 6) • MIR200B (MicroRNA 200b) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1)
|
PMAIP1 overexpression
1year
Single cell Analysis identifies new insights into the development of venetoclax resistant in Multiple Myeloma patients (IMW 2023)
Taken together these data underline the complexity of the mechanisms involved in venetoclax resistance and showed that the loss of BCL2 dependency can be due to NOXA downregulation and upregulation of MCL-1 and RUNX-1. Therefore, the use of agents that can prime BCL2-dependency through upregulation of NOXA and shifting BIM loading to BCL2 (RUNX1 inhibitors) could be explored in combination with venetoclax in MM patients who acquire MCL1 dependence following treatment.
Clinical • IO biomarker
|
RUNX1 (RUNX Family Transcription Factor 1) • SDC1 (Syndecan 1)
|
MCL1 expression • RUNX1 overexpression • PMAIP1 overexpression
|
Venclexta (venetoclax)